Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial
Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study asse...
Saved in:
| Published in | Clinical and translational science Vol. 14; no. 5; pp. 1886 - 1893 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.09.2021
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1752-8054 1752-8062 1752-8062 |
| DOI | 10.1111/cts.13042 |
Cover
| Abstract | Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single‐center, randomized, double‐blind, placebo‐controlled, three‐way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end‐tidal carbon dioxide (ETCO2) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4‐h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2, SpO2, or respiratory rate. The most commonly reported treatment‐emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. |
|---|---|
| AbstractList | Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single‐center, randomized, double‐blind, placebo‐controlled, three‐way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end‐tidal carbon dioxide (ETCO
2
) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO
2
) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO
2
or reduced SpO
2
primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4‐h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO
2
, SpO
2
, or respiratory rate. The most commonly reported treatment‐emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. Abstract Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single‐center, randomized, double‐blind, placebo‐controlled, three‐way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end‐tidal carbon dioxide (ETCO2) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4‐h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2, SpO2, or respiratory rate. The most commonly reported treatment‐emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single‐center, randomized, double‐blind, placebo‐controlled, three‐way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end‐tidal carbon dioxide (ETCO2) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4‐h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2, SpO2, or respiratory rate. The most commonly reported treatment‐emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small‐peptidic structure limits CNS entry, minimizing potential CNS‐mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single‐center, randomized, double‐blind, placebo‐controlled, three‐way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end‐tidal carbon dioxide (ETCO2) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4‐h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2, SpO2, or respiratory rate. The most commonly reported treatment‐emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small-peptidic structure limits CNS entry, minimizing potential CNS-mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single-center, randomized, double-blind, placebo-controlled, three-way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end-tidal carbon dioxide (ETCO2 ) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2 ) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4-h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2 , SpO2 , or respiratory rate. The most commonly reported treatment-emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression.Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small-peptidic structure limits CNS entry, minimizing potential CNS-mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single-center, randomized, double-blind, placebo-controlled, three-way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end-tidal carbon dioxide (ETCO2 ) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO2 ) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO2 or reduced SpO2 primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4-h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO2 , SpO2 , or respiratory rate. The most commonly reported treatment-emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of pruritus. Its hydrophilic, small-peptidic structure limits CNS entry, minimizing potential CNS-mediated adverse events (AEs). This study assessed the effect of difelikefalin on key relevant measures of respiratory depression in healthy volunteers. This single-center, randomized, double-blind, placebo-controlled, three-way crossover study enrolled healthy, nonsmoking volunteers. Subjects were randomized to 1 of 3 treatment sequences of difelikefalin (1.0 or 5.0 mcg/kg i.v.) or placebo on sequential days with an intervening 24 (±2) h washout period. The primary end points included incidence of increased end-tidal carbon dioxide (ETCO ) greater than or equal to 10 mm Hg versus baseline or a level greater than 50 mm Hg sustained greater than or equal to 30 seconds, and incidence of reduction in saturation of peripheral oxygen (SpO ) to less than 92% sustained greater than or equal to 30 seconds. Secondary end points included incidence of reduced respiratory rate and other safety assessments. Fifteen subjects were randomized and completed the study. No subject on placebo or difelikefalin met the increased ETCO or reduced SpO primary end point criteria for respiratory depression. All respiratory measures in each group remained near baseline values during 4-h postdose observations. No subject met the reduced respiratory rate criterion or experienced clinically significant changes in ETCO , SpO , or respiratory rate. The most commonly reported treatment-emergent AEs (TEAEs; ≥20% of subjects) were paresthesia, hypoesthesia, and somnolence in the difelikefalin arms. All TEAEs were mild and resolved without intervention. Difelikefalin 1.0 and 5.0 mcg/kg i.v. did not produce respiratory depression. |
| Author | Setnik, Beatrice S. Torjman, Marc C. Munera, Catherine L. Bagal, Sukirti N. Stauffer, Joseph W. Viscusi, Eugene R. |
| AuthorAffiliation | 3 Department of Pharmacology and Toxicology University of Toronto Toronto Ontario Canada 2 Cara Therapeutics Stamford Connecticut USA 1 Department of Anesthesiology Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia Pennsylvania USA 4 Altasciences Montreal Quebec Canada |
| AuthorAffiliation_xml | – name: 3 Department of Pharmacology and Toxicology University of Toronto Toronto Ontario Canada – name: 1 Department of Anesthesiology Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia Pennsylvania USA – name: 2 Cara Therapeutics Stamford Connecticut USA – name: 4 Altasciences Montreal Quebec Canada |
| Author_xml | – sequence: 1 givenname: Eugene R. surname: Viscusi fullname: Viscusi, Eugene R. organization: Sidney Kimmel Medical College at Thomas Jefferson University – sequence: 2 givenname: Marc C. surname: Torjman fullname: Torjman, Marc C. organization: Sidney Kimmel Medical College at Thomas Jefferson University – sequence: 3 givenname: Catherine L. surname: Munera fullname: Munera, Catherine L. organization: Cara Therapeutics – sequence: 4 givenname: Joseph W. surname: Stauffer fullname: Stauffer, Joseph W. organization: Cara Therapeutics – sequence: 5 givenname: Beatrice S. surname: Setnik fullname: Setnik, Beatrice S. organization: Altasciences – sequence: 6 givenname: Sukirti N. surname: Bagal fullname: Bagal, Sukirti N. email: sbagal@caratherapeutics.com organization: Cara Therapeutics |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33982405$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Us1uEzEQXqEi-gMHXgBZ4gJS0nrXa6_DAamKClSqxIFytsbecXDqrBd7tyiceARuvB9PgtOkFa3AF3u--eabH89hsdeFDovieUmPy3xOzJCOS0br6lFxUDa8mkoqqr27N6_3i8OUlpQKJiR_UuwzNpNVTflB8evMWjQDCZa0zqJ3V2jBu25CgCT02eWukVxB3wMJvQuuJREN9kOIBBahc2mYkNBlMPUuQobXpMU-m8mF7g05JRG6Nqzcd2wnpA2j9vj7x0-dU2S792BQhwyY0A0xeI8tGaID_7R4nOtI-Gx3HxWf351dzj9MLz6-P5-fXkwN3zTHLLCWNabSjQHNGBdS0LIEoTkHTinMSquxaYzRtRRCWkqN4SDrWSXBcsGOivOtbhtgqfroVhDXKoBTN0CICwVxcMajYjoPzSLWWtN6ZqVEI2oEI_MgKWt01nq71epHvcLWYG4J_D3R-57OfVGLcK0kp7UsqyzwaicQw9cR06BWLhn0HjoMY1IVrwSjTc6WqS8fUJdhjF0eVWZJ2pSClbPMevF3RXel3P5_JpxsCSaGlCJaZdwAg9v8BjivSqo2G6byhqmbDcsRrx9E3Ir-i7tT_-Y8rv9PVPPLT9uIP7mR5EI |
| CitedBy_id | crossref_primary_10_3389_fphar_2023_1203642 crossref_primary_10_1080_1744666X_2023_2272048 crossref_primary_10_1093_ndt_gfad245 crossref_primary_10_3390_molecules28124848 crossref_primary_10_1111_cts_13173 crossref_primary_10_1152_japplphysiol_00509_2023 crossref_primary_10_1016_j_peptides_2023_171004 crossref_primary_10_1021_acschemneuro_5c00075 crossref_primary_10_1186_s12882_024_03790_w crossref_primary_10_3390_ph15080934 crossref_primary_10_1007_s40262_023_01262_2 crossref_primary_10_1111_cts_13538 crossref_primary_10_3389_fphar_2024_1476587 crossref_primary_10_3389_fphar_2022_837671 crossref_primary_10_1007_s40265_021_01619_6 crossref_primary_10_3389_fnmol_2022_926596 crossref_primary_10_1007_s40267_022_00945_3 crossref_primary_10_1080_17512433_2023_2197209 crossref_primary_10_1080_0886022X_2024_2384590 crossref_primary_10_1007_s00210_023_02912_9 crossref_primary_10_1007_s00940_022_3390_8 crossref_primary_10_1080_14728214_2024_2345643 |
| Cites_doi | 10.1093/bja/aeh180 10.1197/j.aem.2005.12.017 10.1016/j.jpain.2015.01.340 10.1213/01.ane.0000269489.26048.63 10.1016/j.ekir.2020.01.006 10.1097/ALN.0b013e318238bba6 10.2174/138161212803582469 10.2340/00015555-1353 10.1097/AJP.0b013e3181c49e3a 10.1016/0166-2236(95)80024-V 10.2217/pmt.14.19 10.4187/respcare.04919 10.1016/j.jpain.2015.01.341 10.1007/s00213-010-1819-6 10.1056/NEJMoa1912770 10.1111/jcpt.12404 10.1016/0168-0102(95)00933-K 10.1016/j.ddtec.2011.07.007 10.1007/s002130100788 10.1007/BF03012664 10.1681/ASN.20203110S122d 10.1017/S1481803500012549 10.1213/00000539-199212000-00015 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics – notice: 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TK 7TM 7U9 7X7 7XB 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7N M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 5PM DOA |
| DOI | 10.1111/cts.13042 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Effect of difelikefalin on respiratory depression |
| EISSN | 1752-8062 |
| EndPage | 1893 |
| ExternalDocumentID | oai_doaj_org_article_3b982fee4bb049f88ec64eac8405037b PMC8504812 33982405 10_1111_cts_13042 CTS13042 |
| Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Cara Therapeutics |
| GroupedDBID | --- 05W 0R~ 10A 1OC 24P 29B 31~ 4.4 52S 53G 5GY 5VS 7X7 8-1 8FE 8FH 8FI 8FJ AAHHS AANHP AAZKR ABDBF ABUWG ACBWZ ACCFJ ACCMX ACRPL ACUHS ACXQS ACYXJ ADKYN ADNMO ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AFZJQ AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BDRZF BENPR BHPHI BPHCQ BRXPI BVXVI CAG CCPQU COF CS3 DIK EBD EBS EJD EMOBN ESX F5P FEDTE FYUFA G-S GODZA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IHR ITC KQ8 LH4 LK8 LW6 M7P MY~ O9- OIG OK1 P2P PIMPY PQQKQ PROAC QB0 ROL RPM SUPJJ SV3 TUS UKHRP WIN XG1 AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PQGLB 3V. 7QP 7T5 7TK 7TM 7U9 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c5752-3fa3d37c2b7cab335686011a6b55a500a91fbe77ccb48668f00cc5a84928af563 |
| IEDL.DBID | DOA |
| ISSN | 1752-8054 1752-8062 |
| IngestDate | Wed Aug 27 01:12:04 EDT 2025 Thu Aug 21 13:59:06 EDT 2025 Fri Sep 05 05:05:52 EDT 2025 Wed Aug 13 07:02:25 EDT 2025 Mon Jul 21 05:23:50 EDT 2025 Tue Jul 01 01:05:36 EDT 2025 Thu Apr 24 22:58:55 EDT 2025 Wed Jan 22 16:28:54 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Attribution-NonCommercial 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5752-3fa3d37c2b7cab335686011a6b55a500a91fbe77ccb48668f00cc5a84928af563 |
| Notes | Funding information Cara Therapeutics sponsored this study. Clinical trial number and registry URL: Not applicable (NA). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/3b982fee4bb049f88ec64eac8405037b |
| PMID | 33982405 |
| PQID | 2580716319 |
| PQPubID | 2029979 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3b982fee4bb049f88ec64eac8405037b pubmedcentral_primary_oai_pubmedcentral_nih_gov_8504812 proquest_miscellaneous_2526307503 proquest_journals_2580716319 pubmed_primary_33982405 crossref_citationtrail_10_1111_cts_13042 crossref_primary_10_1111_cts_13042 wiley_primary_10_1111_cts_13042_CTS13042 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2021 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: September 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Clinical and translational science |
| PublicationTitleAlternate | Clin Transl Sci |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2010; 12 2011; 115 2015; 16 2007; 105 2011 2006; 13 2020; 382 2015; 127 2012; 18 1995; 18 1992; 75 1995; 42 2012; 92 2001; 157 2020; 5 2014; 4 2010; 26 2004; 93 2020; 31 1995; 23 2010; 210 2016; 41 2016; 61 2003; 521 2012; 9 e_1_2_10_23_1 Kaneko Y (e_1_2_10_30_1) 1995; 42 e_1_2_10_24_1 e_1_2_10_21_1 Warner M (e_1_2_10_10_1) 2011 e_1_2_10_22_1 Stein C (e_1_2_10_4_1) 2003; 521 e_1_2_10_20_1 Stauffer JW (e_1_2_10_32_1) 2015; 127 e_1_2_10_2_1 Stauffer JW (e_1_2_10_31_1) 2015; 127 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_11_1 Wooldridge TD (e_1_2_10_33_1) 2020; 31 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 115 start-page: 1363 issue: 6 year: 2011 end-page: 1381 article-title: Molecular mechanisms of opioid receptor‐dependent signaling and behavior publication-title: Anesthesiology – year: 2011 – volume: 210 start-page: 109 issue: 2 year: 2010 end-page: 119 article-title: Kappa opioids and the modulation of pain publication-title: Psychopharmacology – volume: 16 start-page: S81 issue: 4 suppl year: 2015 article-title: CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy [abstract 422] publication-title: J Pain – volume: 42 start-page: 126 issue: 3–4 year: 1995 end-page: 130 article-title: Clinical perspectives on capnography during sedation and general anesthesia in dentistry publication-title: Anesth Prog – volume: 31 start-page: 22 issue: suppl year: 2020 end-page: 23 article-title: Efficacy and safety of difelikefalin for moderate‐to‐severe CKD–associated pruritus: a global phase 3 study in hemodialysis patients (KALM‐2) [abstract FR‐OR24] publication-title: J Am Soc Nephrol – volume: 23 start-page: 121 issue: 2 year: 1995 end-page: 145 article-title: Molecular biology of the opioid receptors: structures, functions and distributions publication-title: Neurosci Res – volume: 382 start-page: 222 issue: 3 year: 2020 end-page: 232 article-title: A phase 3 trial of difelikefalin in hemodialysis patients with pruritus publication-title: N Engl J Med – volume: 12 start-page: 397 issue: 5 year: 2010 end-page: 404 article-title: A comparative evaluation of capnometry versus pulse oximetry during procedural sedation and analgesia on room air publication-title: CJEM – volume: 4 start-page: 317 issue: 4 year: 2014 end-page: 325 article-title: Opioid‐induced respiratory depression in the acute care setting: a compendium of case reports publication-title: Pain Management – volume: 41 start-page: 371 issue: 4 year: 2016 end-page: 382 article-title: Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? publication-title: J Clin Pharm Ther – volume: 93 start-page: 212 issue: 2 year: 2004 end-page: 223 article-title: Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data publication-title: Br J Anaesth – volume: 9 start-page: e23 issue: 1 year: 2012 end-page: e31 article-title: Opioid peptides: potential for drug development publication-title: Drug Disc Today Technol – volume: 92 start-page: 555 issue: 5 year: 2012 end-page: 560 article-title: Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review publication-title: Acta Derm Venereol – volume: 5 start-page: 600 issue: 5 year: 2020 end-page: 610 article-title: Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients publication-title: Kidney Int Rep – volume: 521 start-page: 69 year: 2003 end-page: 76 article-title: Opioid receptors on peripheral sensory neurons publication-title: Adv Exp Med Biol – volume: 105 start-page: 412 issue: 2 year: 2007 end-page: 418 article-title: Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient‐controlled analgesia publication-title: Anesth Analg – volume: 61 start-page: 1397 issue: 10 year: 2016 end-page: 1416 article-title: Monitoring exhaled carbon dioxide publication-title: Respir Care – volume: 16 start-page: S81 issue: 4 suppl year: 2015 article-title: CR845, a novel peripherally‐acting kappa opioid receptor agonist, has low abuse potential compared with pentazocine [abstract 421] publication-title: J Pain – volume: 26 start-page: S10 issue: Suppl 10 year: 2010 end-page: 15 article-title: Delta and kappa opioid receptors as suitable drug targets for pain publication-title: Clin J Pain – volume: 18 start-page: 5994 issue: 37 year: 2012 end-page: 6004 article-title: Non‐analgesic effects of opioids: opioid‐induced respiratory depression publication-title: Curr Pharm Des – volume: 18 start-page: 69 issue: 2 year: 1995 end-page: 70 article-title: Opioid receptors: past, present and future publication-title: Trends Neurosci – volume: 75 start-page: 965 issue: 6 year: 1992 end-page: 971 article-title: Time‐course of respiratory depression after an alfentanil infusion‐based anesthetic publication-title: Anesth Analg – volume: 42 start-page: 677 issue: 8 year: 1995 end-page: 684 article-title: Sedative and ventilatory effects of midazolam infusion: effect of flumazenil reversal publication-title: Can J Anaesth – volume: 157 start-page: 151 issue: 2 year: 2001 end-page: 162 article-title: Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans publication-title: Psychopharmacology – volume: 13 start-page: 500 issue: 5 year: 2006 end-page: 504 article-title: Does end‐tidal carbon dioxide monitoring detect respiratory events prior to current sedation monitoring practices? publication-title: Acad Emerg Med – volume: 127 start-page: S96 year: 2015 end-page: S97 article-title: CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy [abstract] publication-title: Postgrad Med – volume: 127 start-page: S97 year: 2015 article-title: Analgesic efficacy of the peripheral kappa‐opioid agonist CR845 in laparoscopic hysterectomy [abstract] publication-title: Postgrad Med – ident: e_1_2_10_28_1 doi: 10.1093/bja/aeh180 – ident: e_1_2_10_18_1 doi: 10.1197/j.aem.2005.12.017 – ident: e_1_2_10_15_1 doi: 10.1016/j.jpain.2015.01.340 – ident: e_1_2_10_29_1 doi: 10.1213/01.ane.0000269489.26048.63 – ident: e_1_2_10_20_1 doi: 10.1016/j.ekir.2020.01.006 – ident: e_1_2_10_6_1 doi: 10.1097/ALN.0b013e318238bba6 – ident: e_1_2_10_8_1 doi: 10.2174/138161212803582469 – volume: 127 start-page: S97 year: 2015 ident: e_1_2_10_32_1 article-title: Analgesic efficacy of the peripheral kappa‐opioid agonist CR845 in laparoscopic hysterectomy [abstract] publication-title: Postgrad Med – ident: e_1_2_10_21_1 – ident: e_1_2_10_5_1 doi: 10.2340/00015555-1353 – ident: e_1_2_10_11_1 doi: 10.1097/AJP.0b013e3181c49e3a – ident: e_1_2_10_2_1 doi: 10.1016/0166-2236(95)80024-V – ident: e_1_2_10_9_1 doi: 10.2217/pmt.14.19 – ident: e_1_2_10_24_1 doi: 10.4187/respcare.04919 – ident: e_1_2_10_16_1 doi: 10.1016/j.jpain.2015.01.341 – volume: 42 start-page: 126 issue: 3 year: 1995 ident: e_1_2_10_30_1 article-title: Clinical perspectives on capnography during sedation and general anesthesia in dentistry publication-title: Anesth Prog – volume-title: Drug Poisoning Deaths in the United States, 1980‐2008 year: 2011 ident: e_1_2_10_10_1 – ident: e_1_2_10_7_1 doi: 10.1007/s00213-010-1819-6 – ident: e_1_2_10_19_1 doi: 10.1056/NEJMoa1912770 – volume: 127 start-page: S96 year: 2015 ident: e_1_2_10_31_1 article-title: CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy [abstract] publication-title: Postgrad Med – ident: e_1_2_10_14_1 doi: 10.1111/jcpt.12404 – ident: e_1_2_10_3_1 doi: 10.1016/0168-0102(95)00933-K – ident: e_1_2_10_13_1 doi: 10.1016/j.ddtec.2011.07.007 – ident: e_1_2_10_12_1 doi: 10.1007/s002130100788 – ident: e_1_2_10_25_1 – ident: e_1_2_10_26_1 doi: 10.1007/BF03012664 – ident: e_1_2_10_17_1 – volume: 31 start-page: 22 year: 2020 ident: e_1_2_10_33_1 article-title: Efficacy and safety of difelikefalin for moderate‐to‐severe CKD–associated pruritus: a global phase 3 study in hemodialysis patients (KALM‐2) [abstract FR‐OR24] publication-title: J Am Soc Nephrol doi: 10.1681/ASN.20203110S122d – volume: 521 start-page: 69 year: 2003 ident: e_1_2_10_4_1 article-title: Opioid receptors on peripheral sensory neurons publication-title: Adv Exp Med Biol – ident: e_1_2_10_22_1 – ident: e_1_2_10_23_1 doi: 10.1017/S1481803500012549 – ident: e_1_2_10_27_1 doi: 10.1213/00000539-199212000-00015 |
| SSID | ssj0063685 |
| Score | 2.3836794 |
| Snippet | Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the treatment of... Abstract Difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, is under development for the... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1886 |
| SubjectTerms | Adolescent Adult Adverse events Agonists Analgesics Carbon dioxide Carbon Dioxide - analysis Central nervous system Cross-Over Studies Double-Blind Method Double-blind studies Female Healthy Volunteers Hemodialysis Humans Incidence Kidney diseases Male Middle Aged Narcotics Nervous system Opioid receptors (type kappa) Oxygen Saturation - drug effects Paresthesia Piperidines - administration & dosage Piperidines - adverse effects Placebos Placebos - administration & dosage Placebos - adverse effects Pruritus Pruritus - drug therapy Pulse oximetry Receptors, Opioid, kappa - agonists Respiration Respiratory Insufficiency - chemically induced Respiratory Insufficiency - diagnosis Respiratory Insufficiency - epidemiology Respiratory Rate - drug effects Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgL4p9AQQZx6GEjNvFPHC6oVFQVUrnQSnuLPI7dRl3i0N29cOIRuPF-PAljrzewonBLbEu2MzOeGc_kG0JeAa-14srmUGqec2MgVwIJgszDCstsDW34d_j4ozw65R9mYpYu3BYprXJzJsaDuvUm3JG_LoVCbSiRY94OX_JQNSpEV1MJjevkRoGmSuDqajY6XDKAq8cfIgVKPdomCVkoZPKY5SIUQubllj6KsP1X2Zp_p0z-acpGXXR4h9xORiTdX1P9Lrlm-3vk5nEKk98nP9aYxNQ72nbOzrsL69De7idU00UsfINnHL3Qw6CpHzrftRQPPjug_031mQ9guhPqe2wc4_B0TJnt39B9ihqu9Z-7r7ad0NavYG5_fvsOOAW-xzQv8NiQ8uDntqWxOsgDcnr4_uTgKE8VGHIjwkdjTrOWVaaEymhgTEiFDlyhJQgRSinounBgqwpJzJWUyk2nxggkfl0q7YRkD8lO73v7mFCpgRcAU1cA-pTAtbK1YJoLZRyagFVG9jZ0aEyCJw9VMubNxk1BkjWRZBl5OQ4d1pgcVw16F4g5Dggw2rHBX541SSobBrUqnbUcF8Zrp5Q1kqMqwhWKKasgI7sbVmiSbC-a35yYkRdjN0plCLXo3vpVGFNKFmPEGXm05pxxJYzhpDhBRqotntpa6nZP351H5G8lArwP7m0vct-_d98cnHyKD0_-v4On5FYZknRi0twu2VleruwztLKW8DyK0i9G6SqS priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaqIiEuqLwDBRnEoYeNtIkfceBUKqoKqQiJVuot8jh2ibrEUXf30hM_obf-P34JY-ehrigSt8SZyHbm6Xj8DSHvgZdacWVTyDVPuTGQKoEMQeFhmWW2hDqcHT7-Ko9O-ZczcbZFPo5nYXp8iOmHW9CMaK-DgmtY3lJys1qGUsYc7e-9LHj9AOvMv41mWAZk9XgaUqDKY2AywAqFNJ7p1Q1nFDH77wo0_86XvB3HRkd0uEMeDhEk3e9Z_ohs2fYxuX887JE_ITc9IDH1jtaNw0leWIfBdjujmi5j1Rs0cPRCd52mvmt8U1O0erbDxTfV5z4g6c6ob7Fx2oSnU75s-4HuU3Rvtf_ZXNl6Rmu_hoX9_esasAu8jzle4LFhSIJf2JrG0iBPyenh55ODo3Qov5AaET4ac5rVrDA5FEYDY0IqXL1lWoIQoY6CLjMHtiiQv1xJqdx8boxAzpe50k5I9oxst761LwiVGngGMHcZ4IISuFa2FExzoYzD-K9IyN7Ih8oM2OShRMaiGtcoyLIqsiwh7ybSrgfkuIvoU2DmRBAwtGODvzyvBpWsGJQqd9ZyHBgvnVLWSI5-CEco5qyAhOyOolANir2scqEwKJNouBLydnqMKhn2WXRr_TrQ5JLFDeKEPO8lZxoJY9gpdpCQYkOmNoa6-aRtfkTYbyUCtg_ObS9K379nXx2cfI8XL_-f9BV5kIdsnZg9t0u2V5dr-xrDrRW8iWr1By_7KqQ priority: 102 providerName: Wiley-Blackwell |
| Title | Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13042 https://www.ncbi.nlm.nih.gov/pubmed/33982405 https://www.proquest.com/docview/2580716319 https://www.proquest.com/docview/2526307503 https://pubmed.ncbi.nlm.nih.gov/PMC8504812 https://doaj.org/article/3b982fee4bb049f88ec64eac8405037b |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: KQ8 dateStart: 20160101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: KQ8 dateStart: 20080501 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: DOA dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: ABDBF dateStart: 20080401 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: RPM dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: 7X7 dateStart: 20160201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: BENPR dateStart: 20160201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVWIB databaseName: KBPluse Wiley Online Library: Open Access customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: AVUZU dateStart: 20080901 isFulltext: true titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559 providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1752-8062 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063685 issn: 1752-8054 databaseCode: 24P dateStart: 20080101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgL4k1KWRnEoYddsYkfcbi1VasKqVUFrbS3yOPYJeoSR93dCyd-Ajf-H7-EsZONuqKIC5cocSz58Y3HM_L4G0LeAS-04spOINN8wo2BiRIICAoPSy2zBVTh7vDJqTy-4B9nYnYj1VeICevogbuJe8-gUJmzlgOgMeuUskZy1BbomIgpyyFoX9zG1s5Up4NloFWPVyEFrne0SnpOoRDDY5aLkAKZZxs7USTsv83K_DNY8qYRG3eho0fkYW8-0r2u24_JHds8IfdP-gPyp-Rnx0ZMvaNV7ey8vrIOLe1mTDVdxJQ3qN3olW5bTX1b-7qiqPJsi5431Zc-0OiOqW-wcDiBp0OwbPOB7lHc2yr_tf5mqzGt_Arm9tf3H4BN4HcM8AKPBX0E_NxWNOYFeUYujg7PD44nfe6FiRFh0pjTrGK5ySA3GhgTUqHrlmoJQoQkCrpIHdg8R3C5klK56dQYgbAXmdJOSPacbDW-sS8JlRp4iui5FBA04FrZQjDNhTIOjb88IbtrHErTE5OH_Bjzcu2gIGRlhCwhb4eqbcfGcVul_QDmUCEQaMcCFKuyF6vyX2KVkJ21KJT9ql6UmVBokUnUWgl5M_zG9RgOWXRj_SrUySSLp8MJedFJztATxrBRbCAh-YZMbXR1809Tf4mc30oEYh8c226Uvr-Pvjw4_xxftv_HNLwiD7IQxBOD6nbI1vJ6ZV-jFbaEEbmb8TN85rN8RO7tH56efRrFRfgbxMo28w |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkYAL4p9AAYNA6mEjduOfOEgIlUK1pd1e2Ep7C7Zjl6hLHLq7QnDiEbjxFjwUT8LYmwRWFG69JY4VjzWT-cmMv0HosaKZFFSYWCWSxlRrFQsGDAHhIQNDTKYKf3Z4dMCHh_TNhE3W0I_2LIwvq2x1YlDUhdP-H_nThAmwhhwk5kX9MfZdo3x2tW2hsRSLPfP5E4Rss-e7r4C_T5Jk5_V4exg3XQViDa5JEhMrSUFSnahUS0UI4wKCkoHkijHfHkBmA6tMmgLZVHAubL-vNYMNZYmQlnEC7z2HzlPSpx6rP510AR73YO7hACYsI8AXapCMfOWQns9842WarNi_0CbgNN_27xLNP13nYPt2rqDLjdOKt5ZSdhWtmeoaujBq0vLX0fclBjJ2FhelNdPy2Fjw76selngWGu2ATsXHsq4ldnXpygKDojU1xPtYHjkP3tvDroLBLu-PuxLd6hnewmBRC_eh_GKKHi7cQk3Nz6_fFCwB96GsTDkYaOrup6bAoRvJDXR4Jry5idYrV5nbCHOp6ECpvh0oiGEVlcJkjEjKhLbgcqYR2mz5kOsGDt135ZjmbVgELMsDyyL0qJtaLzFATpv00jOzm-Bhu8OAOznKGy2QE5WJxBpDgTCaWSGM5hRMH1DI-iRVEdpoRSFvdMks_y35EXrYPQYt4FM7sjJu4ecknIScdIRuLSWno4QQWBQWiFC6IlMrpK4-qcr3AWlcMA8nBHvbDNL3793n2-O34eLO_3fwAF0cjkf7-f7uwd5ddCnxBUKhYG8Drc9PFuYeeHhzdT98Vhi9O-vv-Bdu1Gak |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkSouiH9SChgEUg8bddc_iYOEUGlZtZRWSLTS3oLt2CXqNg7dXSE48QjceBcehydh7E0CKwq33hLbij2a8fzEn2cQeqJYJgUTJlZEsphprWLBgSEgPHRgqMlU4e8O7x8kO0fs9YiPltCP9i6Mh1W2OjEo6sJp_498g3AB1jABidmwDSzi7fbwRf0x9hWk_ElrW05jLiJ75vMnCN8mz3e3gddPCRm-OtzaiZsKA7EGN4XE1Epa0FQTlWqpKOWJgABlIBPFuS8VILOBVSZNgQQmkkTYfl9rDsRlREjLEwrfvYQup5RRDydLR12wl_jE7uEyJkwjwC9qshp5FJGeTnwRZkYWbGEoGXCen_s3XPNPNzrYweE1dLVxYPHmXOKuoyVT3UAr-80R_U30fZ4PGTuLi9KacXliLPj6VQ9LPAlFd0C_4hNZ1xK7unRlgUHpmhpifyyPnU_k28OugsYOA4A7uG71DG9isK6FOy2_mKKHCzdTY_Pz6zcFU8B7gJgpBw0NBn9sChwqk9xCRxfCm9touXKVuYtwIhUbKNW3AwXxrGJSmIxTybjQFtzPNELrLR9y3aRG9xU6xnkbIgHL8sCyCD3uhtbzfCDnDXrpmdkN8Cm8Q4M7O84bjZBTlQlijWGwMJZZIYxOGJhBWCHv01RFaK0VhbzRK5P89y6I0KOuGzSCP-aRlXEzP4YkNJxPR-jOXHK6lVAKk8IEEUoXZGphqYs9VfkhZB0X3KcWAtrWg_T9m_p86_BdeFj9PwUP0Qrs4PzN7sHePXSFeKxQwO6toeXp2czcB2dvqh6EXYXR-4vexr8AFMFq3w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+difelikefalin%2C+a+selective+kappa+opioid+receptor+agonist%2C+on+respiratory+depression%3A+A+randomized%2C+double%E2%80%90blind%2C+placebo%E2%80%90controlled+trial&rft.jtitle=Clinical+and+translational+science&rft.au=Eugene+R.+Viscusi&rft.au=Marc+C.+Torjman&rft.au=Catherine+L.+Munera&rft.au=Joseph+W.+Stauffer&rft.date=2021-09-01&rft.pub=Wiley&rft.issn=1752-8054&rft.eissn=1752-8062&rft.volume=14&rft.issue=5&rft.spage=1886&rft.epage=1893&rft_id=info:doi/10.1111%2Fcts.13042&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_3b982fee4bb049f88ec64eac8405037b |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon |